| Literature DB >> 24172244 |
Hamza M Abosadiya1, Siti Aishah Hasbullah, Mukram Mohamed Mackeen, Seow Chew Low, Nazlina Ibrahim, Mamoru Koketsu, Bohari M Yamin.
Abstract
C-5-bromo-2-hydroxyphenylcalix[4]-2-methylresorcinarene (I) was synthesized by cyclocondensation of 5-bromo-2-hydroxybenzaldehyde and 2-methylresorcinol in the presence of concentrated HCl. Compound I was characterized by infrared and nuclear magnetic resonance spectroscopic data. X-ray analysis showed that this compound crystallized in a triclinic system with space group of Pī, a = 15.9592(16)Å, b = 16.9417(17)Å, c = 17.0974(17)Å, α = 68.656(3)°, β = 85.689(3)°, γ = 81.631(3)°, Z = 2 and V = 4258.6(7)Å3. The molecule adopts a chair (C2h) conformation. The thermal properties and antioxidant activity were also investigated. It was strongly antiviral against HSV-1 and weakly antibacterial against Gram-positive bacteria. Cytotoxicity testing on Vero cells showed that it is non-toxic, with a CC50 of more than 0.4 mg/mL.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24172244 PMCID: PMC6270492 DOI: 10.3390/molecules181113369
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of C-5-bromo-2-hydroxyphenylcalix[4]-2-methylresorcinarene (I).
Figure 11H-NMR spectrum of C-5-bromo-2-hydroxyphenylcalix[4]-2-methylresorcinarene in DMSO-d6.
Figure 2The molecular structure of C-5-bromo-2-hydroxyphenylcalix[4]-2-methyl-resorcinarene drawn at 50% probability ellipsoid. The hydrogen atoms and solvent molecules are not shown for clarity.
Selected bond lengths and angles of C-5-bromo-2-hydroxyphenylcalix[4]-2-methylresorcinarene (I).
| Bond | Length Å | Bond | Angles ° |
|---|---|---|---|
| Br1-C13 | 1.905(6) | C12-C13-Br1 | 120.0(4) |
| Br2-C27 | 1.902(5) | C26-C27-Br2 | 120.6(4) |
| Br3-C41 | 1.904(6) | C40-C41-Br3 | 118.8(4) |
| Br4-C55 | 1.905(5) | C54-C55-Br4 | 119.8(4) |
| O1-C3 | 1.381(6) | O1-C3-C2 | 116.9(5) |
| O2-C5 | 1.390(6) | O2-C5-C4 | 117.2(5) |
| O3-C10 | 1.359(7) | O3-C10-C11 | 122.6(5) |
| O4-C16 | 1.366(6) | O4-C16-C15 | 116.0(5) |
| N1-C59 | 1.319(8) | C59-N1-C58 | 120.6(6) |
| N2-C62 | 1.314(9) | C62-N2-C60 | 120.6(6) |
| N3-C65 | 1.325(8) | C65-N3-C64 | 121.5(5) |
| N4-C68 | 1.327(8) | C68-N4-C67 | 120.8(6) |
Figure 3Molecular packing of C-5-bromo-2-hydroxyphenylcalix[4]-2-methylresorcinarene, viewed down the b axis. Dashed lines denote O—H….O and C—H….O hydrogen bonds and the non-hydrogen bonded atoms are omitted for clarity.
Hydrogen geometric parameters (Å) of C-5-bromo-2-hydroxyphenylcalix[4]-2-methylresocinarene.
| D―H….A | D―H | H….A | H….A | D―H….A |
|---|---|---|---|---|
| O1W―H1WB.....O17 | 0.82(6) | 1.94(6) | 2.756(8) | 172(3) |
| O3―H3….O20 | 0.84 | 1.86 | 2.690(6) | 169 |
| O2W―H2WB…..O20 | 0.82(4) | 2.08(4) | 2.895(7) | 173(6) |
| O7―H7….O15 | 0.84 | 1.83 | 2.576(6) | 146 |
| O12―H12….O2W | 0.84 | 1.86 | 2.696(7) | 174 |
| C64―H64B….O1W | 0.98 | 2.60 | 3.514(9) | 155 |
| C66―H66B….O3W | 0.98 | 2.59 | 3.400(9) | 140 |
| C72―H72B….O4 | 0.98 | 2.36 | 3.337(9) | 172 |
| C76―H76A….O18 | 0.98 | 2.59 | 3.440(8) | 145 |
| O1―H1…..O19 ii | 0.84 | 2.08 | 2.821(6) | 148 |
| O1W―H1WA….O13 vii | 0.82(7) | 2.03(7) | 2.815(7) | 161(6) |
| O2W―H2WA….O16 ix | 0.82(3) | 1.91(4) | 2.718(7) | 168(10) |
| O4―H4….O3W iii | 0.84 | 1.9 | 2.668(6) | 152 |
| O5―H5….O7 iv | 0.84 | 2.06 | 2.796(5) | 145 |
| O3W―H3WA….O13 xi | 0.82(5) | 1.96(6) | 2.756(7) | 162(6) |
| O6―H6….O1W iv | 0.84 | 1.89 | 2.718(7) | 170 |
| O3W―H3WB....O14 x | 0.82(5) | 2.13(5) | 2.945(7) | 174(9) |
| O4W―H4WA….O17 viii | 0.82(6) | 1.94(6) | 2.764(8) | 174(7) |
| O8―H8….O18 v | 0.84 | 2.01 | 2.811(6) | 159 |
| O4W―H4WB....O14 iii | 0.82(5) | 1.98(5) | 2.778(10) | 166(7) |
| O9―H9….O4W vi | 0.84 | 1.87 | 2.706(7) | 170 |
| O10―H10….O18 v | 0.84 | 1.91 | 2.730(6) | 165 |
| O11―H11….O1 i | 0.84 | 2.05 | 2.786(5) | 147 |
| C21―H21A….O3W iii | 0.98 | 2.37 | 3.325(9) | 165 |
| C21―H21B….O7 iv | 0.98 | 2.47 | 3.305(7) | 143 |
| C21―H21C….O6 iv | 0.98 | 2.53 | 3.455(8) | 158 |
| C36―H36….O18 v | 0.98 | 2.38 | 3.255(7) | 146 |
| C49―H49B….O1 i | 0.98 | 2.59 | 3.444(6) | 146 |
| C59―H59….O4W vi | 0.95 | 2.51 | 3.441(8) | 167 |
| C61―H61B….O5 iv | 0.98 | 2.57 | 3.509(7) | 160 |
| C75―H75A….O15 iii | 0.98 | 2.53 | 3.453(8) | 157 |
| C78―H78A….O16 ix | 0.98 | 2.59 | 3.331(9) | 133 |
| C79―H79C….O3 ii | 0.98 | 2.55 | 3.487(8) | 161 |
| C80―H80….O16 iii | 0.95 | 2.59 | 3.531(8) | 171 |
Symmetry codes: i = −x, 2 − y, 1 − z; ii = −x, 1 − y, 1 − z; iii = 1 − x, 1 − y, 1 − z; iv = 1 − x, 1 − y, 2 – z; v = x, 1 + y, z; vi = x, 1 + y, 1 + z; vii = x, −1 + y, z; viii = 1 − x, −y, 1 – z; ix = −1 + x, y, z; x = 1 − x, 1 − y, 2 − z; xi = 1 − x, 2 − y, 1 − z.
Figure 4Thermogram of C-5-bromo-2-hydroxyphenylcalix[4]-2-methylresocinarene (I).
Diameter of inhibition zone for antibacterial screening of C-5-bromo-2-hydroxy phenylcalix[4]-2-methylresorcinarene (I).
| Dose (µg) | Diameter of inhibition zone (mm) | ||||
|---|---|---|---|---|---|
| MRSA | Sa | Ef | Ea | Pa | |
| 250 | 13 | 13 | 15 | 6 | 6 |
| 125 | 12 | 12 | 13 | 6 | 6 |
| 62.5 | 12 | 11 | 11 | 6 | 6 |
| 31.25 | 11 | 11 | 11 | 6 | 6 |
| 15.63 | 10 | 10 | 10 | 6 | 6 |
| Antibiotic control (30 µg) | 15 a | 22 b | 23 b | 26 b | 16 b |
| DMSO (solvent control) | 6 | 6 | 6 | 6 | 6 |
Notes: MRSA = methicillin-resistant Staphylococcus aureus; Sa = Staphylococcus aureus; Ef = Enterococcus faecalis; Ea = Enterobacter aerogenes; Pa = Pseudomonas aeruginosa; a = vancomycin; b = chloramphenicol (30 µg). SD inhibition zone = ± 1 mm (biological replicates, 3).
Figure 5Inhibition zones of C-5-bromo-2-hydroxyphenylcalix[4]2-methylresorcinarene (I) against MRSA using the disc diffusion assay tested at concentrations of two-fold dilution. The highest concentration of tested would correspond to 250 μg.
Minimum inhibition concentration (MIC) (mg/mL), minimum bactericidal concentration (MBC) (mg/mL) and selectivity index (SI) of C-5-bromo-2-hydroxophenylcalix[4]-2-methylresorcinarene (I).
| Microorganism | MIC mg/mL | MBC mg/mL | SI |
|---|---|---|---|
| MRSA (Gram-positive) | 1.563 | 25 | 0.256 |
| Sa (Gram-positive) | 6.25 | 12.5 | 0.064 |
| Ef (Gram-positive) | 6.25 | 12.5 | 0.064 |
| Ea (Gram-negative) | >25 | - | - |
| Pa (Gram-negative) | >25 | - | - |
Note: MRSA = methicillin-resistant Staphylococcus aureus); Sa = Staphylococcus aureus); Ef = Enterococcus faecalis; Ea = Enterobacter aerogenes; Pa = Pseudomonas aeruginosa (-ve); SI = selectivity index = CC50/MIC (refer to Section 2.4.3).
Figure 6Percentage of cell survival against concentration of compound C-5-bromo-2-hydroxyphenylcalix[4]-2-methylresorcinarene (I).
Figure 7Plaque formation to determine virus titer.
Crystallographic data and structural refinement of C-5-bromo-2-hydroxy phenylcalix[4]-2-methylresorcinarene.
| Crystal parameters | Data/values | |
|---|---|---|
| CCDC deposition number | 959177 | |
| Empirical formula | C80H108Br4N8O24 | |
| Moiety formula | C56H44Br4O12, 8(C3H7NO), 4(H2O) | |
| Formula weight | 1885.38 | |
| Temperature | 100(2) K | |
| Wavelength λ | 0.71073 Å | |
| Crystal system | Triclinic | |
| Space group | Pī | |
| Unit cell dimensions | α = 68.656(3)° | |
| β = 85.689(3)° | ||
| γ = 81.631(3)° | ||
| Volume | 4258.6(7) Å3 | |
| Z | 2 | |
| Dcal (Mg/m3) | 1.470 | |
| Absorption coefficient | 1.969 mm−1 | |
| F(000) | 1952 | |
| Crystal dimension (mm) | 0.42 × 0.37 × 0.24 | |
| Tmin/Tmax | 0.4918, 0.6494 | |
| Reflections measured | 130536 | |
| Ranges/indices (h,k,l) | −19, 19; −20, 20; −21, 21 | |
| θ limits (º) | 2.8 to 26.0° | |
| Unique reflections | 16701 | |
| Observed reflections (I>2σ(I)) | 11455 | |
| Parameters | 1101 | |
| Goodness of fit on F2 | 1.13 | |
| R1, wR2 (I≥2σ(I)) | 0.0661, 0.1652 | |
| R1,wR2 indices (all data) | 0.1107, 0.1997 | |
| Largest diff. peak and hole | 2.669 and −0.977 e.Å−3 | |